PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 09/11/2017 06:02:12)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 11, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 






Item 7.01 Regulation FD Disclosure.
 
Beginning on September 11, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in 
conferences with investors and analysts during the Rodman & Renshaw 19th Annual Global Investment Conference in New York City, New York. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ Peter S. Garcia
 
 
Peter S. Garcia
 
 
Vice President and Chief Financial Officer




Dated: September 11, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 







Exhibit 99.1

SLIDE1A48.JPG





SLIDE2A48.JPG





SLIDE3A48.JPG





SLIDE4A48.JPG





SLIDE5A48.JPG





SLIDE6A48.JPG





SLIDE7A48.JPG





SLIDE8A46.JPG





SLIDE9A45.JPG





SLIDL97.JPG





SLIDL98.JPG





SLIDL99.JPG





SLIDM01.JPG





SLIDM02.JPG





SLIDM03.JPG





SLIDM04.JPG





SLIDM05.JPG





SLIDM06.JPG





SLIDM07.JPG





SLIDM08.JPG





SLIDM09.JPG





SLIDM10.JPG





SLIDM11.JPG





SLIDM12.JPG





SLIDM13.JPG





SLIDM14.JPG





SLIDM15.JPG





SLIDM16.JPG





SLIDM17.JPG





SLIDM18.JPG





SLIDM19.JPG





SLIDM20.JPG





SLIDM21.JPG





SLIDM22.JPG





SLIDM23.JPG





SLIDM24.JPG





SLIDM25.JPG





SLIDM26.JPG





SLIDM27.JPG





SLIDM28.JPG





SLIDM29.JPG





SLIDM30.JPG





SLIDM31.JPG





SLIDM32.JPG





SLIDM33.JPG





SLIDM34.JPG





SLIDM35.JPG





SLIDM36.JPG





SLIDM37.JPG





SLIDM38.JPG





SLIDM39.JPG





SLIDM40.JPG